Recommendations for the prevention, monitoring, and treatment of infectious complications post-hematopoietic cell transplantation
DOI:
https://doi.org/10.46765/2675-374X.2025v7n1e352Keywords:
Cell Transplantation, Infections, Febrile Neutropenia, VaccinationAbstract
This chapter outlines recommendations for the control and management of infections following hematopoietic cell transplantation. Given the complexity and scope of the subject, the authors chose a format that considers the various interventions available to prevent, minimize, or when appropriate treat infections relevant to the hematopoietic cell transplantation setting. We consider the active and collaborative involvement of the transplant infectious disease specialist in transplantation centers to be essential in ensuring the best possible care for this vulnerable population.
References
1. Santos ES, Lima ACM, Breda GL, Tomaz APO, Nabhan SK, Funke VAM, Nogueira KS. Colonization by multidrug‐resistant bacteria in hematological patients undergoing hematopoietic stem cell transplantation and clinical outcomes: A single‐center retrospective cohort study. Transplant Infectious Disease. 2023;25(5):e14119. https://doi.org/10.1111/tid.14119
2. Girmenia C, Bertaina A, Piciocchi A, Perruccio K, Algarotti A, Busca A, Cattaneo C, Raiola AM, Guidi S, Iori AP, Candoni A, Irrera G, Milone G, Marcacci G, Scimè R, Musso M, Cudillo L, Sica S, Castagna L, Corradini P, Marchesi F, Pastore D, Alessandrino EP, Annaloro C, Ciceri F, Santarone S, Nassi L, Farina C, Viscoli C, Rossolini GM, Bonifazi F, Rambaldi A; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Associazione Microbiologi Clinici Italiani (AMCLI). Incidence, risk factors and outcome of pre-engraftment gramnegative bacteremia after allogeneic and autologous hematopoietic stem cell transplantation: an Italian prospective multicenter survey. Clin Infect Dis. 2017;65(11):1884-96. https://doi.org/10.1093/cid/cix690
3. Perreault SK, Binks B, McManus DS, Topal JE. Evaluation of the negative predictive value of methicillinresistant Staphylococcus aureus nasal swab screening in patients with acute myeloid leukemia. Infect Control Hosp Epidemiol. 2021;42(7):853-6. https://doi.org/10.1017/ice.2020.1299
4. Court JR, Heijmans J, Huynh J, Sieswerda E, Jonge NA, van Dijk K, Sigaloff KCE, Schade RP. Guidance of empirical antimicrobial therapy by surveillance cultures in high-risk neutropenic patients: a retrospective cohort study. Antimicrob Resist Infect Control. 2022;11(1):160. https://doi.org/10.1186/s13756-022-01198-5
5. Nguyen A, Heil E, Patel N, Duffy A, Gilmore S. A single-center evaluation of the risk for colonization or bacteremia with piperacillin–tazobactam- and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis. J Oncol Pharm Pract. 2016;22(2):303-7. https://doi.org/10.1177/1078155214567161
6. Hess AS, Kleinberg M, Sorkin JD, Netzer G, Johnson JK, Shardell M, Thom KA, Harris AD, Roghmann M. C. Prior colonization is associated with increased risk of antibiotic-resistant Gram-negative bacteremia in cancer patients. Diagn Microbiol Infect Dis. 2014;79(1):73-6. https://doi.org/10.1016/j.diagmicrobio.2014.01.022
7. Vehreschild MJGT, Hamprecht A, Peterson L, Schubert S, Häntschel M, Peter S, Schafhausen P, Rohde H, Lilienfeld-Toal M von, Bekeredjian-Ding I, Libam J, Hellmich M, Vehreschild JJ, Cornely OA, Seifert H. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother. 2014;69(12):3387-92. https://doi.org/10.1093/jac/dku305
8. Nesher L, Rolston KVI, Shah DP, Tarrand JT, Mulanovich V, Ariza‐Heredia EJ, Chemaly RF. Fecal colonization and infection with Pseudomonas aeruginosa in recipients of allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2015;17(1):33-8. https://doi.org/10.1111/tid.12323
9. Satlin MJ, Chavda KD, Baker TM, Chen L, Shashkina E, Soave R, Small CB, Jacobs SE, Shore TB, van Besien K, Westblade LF, Schuetz AN, Fowler VG Jr, Jenkins SG, Walsh TJ, Kreiswirth BN. Colonization with levofloxacin-resistant extended-spectrum β-lactamase-producing enterobacteriaceae and risk of bacteremia in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2018;67(11):1720-8. https://doi.org/10.1093/cid/ciy363
10. Ruhnke M, Arnold R, Gastmeier P. Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria. Lancet Oncol. 2014;15(13):e606-19. https://doi.org/10.1016/S1470-2045(14)70344-4
11. Webb BJ, Healy R, Majers J, Burr Z, Gazdik M, Lopansri B, Hoda D, Petersen FB, Ford C. Prediction of bloodstream infection due to vancomycin-resistant enterococcus in patients undergoing leukemia induction or hematopoietic stem-cell transplantation. Clin Infect Dis. 2017;64(12):1753-9. https://doi.org/10.1093/cid/cix232
12. Kamboj M, Cohen N, Huang Y-T, Kerpelev M, Jakubowski A, Sepkowitz KA, Papanicoulaou GA, Seo SK. Impact of empiric treatment for vancomycin-resistant enterococcus in colonized patients early after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(3):594-8. https://doi.org/10.1016/j.bbmt.2018.11.008
13. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young J-AH, Boeckh MA. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143-238. https://doi.org/10.1016/j.bbmt.2009.06.019
14. Mikulska M, Robin C, Neofytos D, Oltolini C, Piekarska A, Reigadas E, Gil L, Chemaly RF, Groll AH, Muñoz P, Teh BW. Management of clostridioides difficile infection in patients with haematological malignancies and after cellular therapy: guidelines from 10th European Conference on Infections in Leukaemia (ECIL-10). EClinicalMed. 2025;87:103371. https://doi.org/10.1016/j.eclinm.2025.103371
15. Brasil. Ministério da Saúde. Portaria MS/GM nº 158, de 4 de fevereiro de 2016. Redefine o regulamento técnico de procedimentos hemoterápicos. Diário Oficial da União. 2016;Seção 1:37-57. [cited 2026 Mar 15]. https://www.cremesp.org.br/library/modulos/legislacao/versao_impressao.php?id=13685
16. Agência Nacional de Vigilância Sanitária (ANVISA). Guia de boas práticas em células e tecidos humanos para uso terapêutico: Guia nº 73/2024, versão 2. Brasília: ANVISA; 2025. [cited 2026 Mar 15]. https://bibliotecadigital.anvisa.gov.br/jspui/handle/anvisa/17752
17. Douglas AP, Slavin MA. Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field. Expert Rev Anti Infect Ther. 2016;14(12):1165-77. https://doi.org/10.1080/14787210.2016.1245613
18. Girmenia C, Barosi G, Piciocchi A, Arcese W, Aversa F, Bacigalupo A, Bandini G, Bosi A, Busca A, Castagnola E, Caselli D, Cesaro S, Ciceri F, Locasciulli A, Locatelli F, Mikulska M, Pagano L, Prete A, Raiola AM, Rambaldi A. Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014;20(8):1080-8. https://doi.org/10.1016/j.bbmt.2014.02.018
19. Corzo-León DE, Satlin MJ, Soave R, Shore TB, Schuetz AN, Jacobs SE, Walsh TJ. Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens. Mycoses. 2015;58(6):325-36. https://doi.org/10.1111/myc.12318
20. Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, Mufti GJ, Kroger N, Zander AR, Heim D, Paluszewska M, Selleslag D, Steinerova K, Ljungman P, Cesaro S, Nihtinen A, Cordonnier C, Vazquez L, López-Duarte M, Lopez J, Cabrera R, Rovira M, Neuburger S, Cornely O, Hunter AE, Marr KA, Dornbusch HJ, Einsele H. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marro
21. Parody R, Martino R, Rovira M, Vazquez L, Vázquez MJ, Cámara R, Blazquez C, Fernández-Avilés F, Carreras E, Salavert M, Jarque I, Martín C, Martínez F, López J, Torres A, Sierra J, Sanz GF; Infectious/Noninfectious Complications Subcommittee of the Grupo Español de Trasplante Hematopoyético (GETH). Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant. 2006;12(7):734-48. https://doi.org/10.1016/j.bbmt.2006.03.007
22. Liu YC, Chien SH, Fan NW, Hu MH, Gau JP, Liu CJ, Yu YB, Liu CY, Hsiao LT, Liu JH, Chiou TJ, Chen PM, Tzeng CH. Incidence and risk factors of probable and proven invasive fungal infection in adult patients receiving allogeneic hematopoietic stem cell transplantation. J Microbiol Immunol Infect. 2016;49(4):567-74. https://doi.org/10.1016/j.jmii.2015.01.002
23. Choi JK, Cho SY, Yoon SS, Moon JH, Kim SH, Lee JH, Kim JS, Cheong JW, Jang JH, Seo BJ, Kim YJ, Lee HJ, Lee J, Lee JW, Lee DG. Epidemiology and risk factors for invasive fungal diseases among allogeneic hematopoietic stem cell transplant recipients in Korea: results of “RISK” Study. Biol Blood Marrow Transplant. 2017;23(10):1773-9. https://doi.org/10.1016/j.bbmt.2017.06.012
24. Cesaro S, Tridello G, Castagnola E, Calore E, Carraro F, Mariotti I, Colombini A, Perruccio K, Decembrino N, Russo G, Maximova N, Baretta V, Caselli D. Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric onco-hematological patients. Eur J Haematol. 2017;99(3):240-8. https://doi.org/10.1111/ejh.12910
25. Busca A, Cinatti N, Gill J, Passera R, Dellacasa CM, Giaccone L, Dogliotti I, Manetta S, Corcione S, Rosa FG. Management of invasive fungal infections in patients undergoing allogeneic hematopoietic stem cell transplantation: the Turin Experience. Front Cell Infect Microbiol. 2022;11:805514. https://doi.org/10.3389/fcimb.2021.805514
26. Papanicolaou GA, Chen M, He N, Martens MJ, Kim S, Batista MV, Bhatt NS, Hematti P, Hill JA, Liu H, Nathan S, Seftel MD, Sharma A, Waller EK, Wingard JR, Young JAH, Dandoy CE, Perales MA, Chemaly RF, Riches M, Ustun C. Incidence and impact of fungal infections in post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical hematopoietic cell transplantation: a center for international blood and marrow transplant research analysis. Transplant Cell Ther. 2024;30(1):114. e1-e16. https://doi.org/10.1016/j.jtct.2023.09.017
27. Mallet V, van Bömmel F, Doerig C, Pischke S, Hermine O, Locasciulli A, Cordonnier C, Berg T, Moradpour D, Wedemeyer H, Ljungman P; ECIL-5. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: Recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis. 2016;16(5):606-17. https://doi.org/10.1016/S1473-3099(16)00118-3
28. Mikulska M, van Bömmel F, Moulia D, Indolfi G, Kefalakes H, von Lilienfeld-Toal M, Pischke S, Hermine O, Moradpour D, Wedemeyer H, Berg T, Ljungman P, Mallet V. Updated recommendations for the management of hepatitis B, C, and E virus infections in patients with haematological malignancies and those undergoing haematopoietic cell transplantation: recommendations from the 9th European Conference on Infections in Leukaemia (ECIL-9). Lancet Haematol. 2025;12(5):e389-99. https://doi.org/10.1016/S2352-3026(25)00049-3
29. Iwanaga M. Epidemiology of HTLV-1 infection and ATL in Japan: an update. Front Microbiol. 2020;11:01124. https://doi.org/10.3389/fmicb.2020.01124
30. Carvalho AMSA, Machado CM. Emerging tropical viral infections: dengue, chikungunya, and zika. In: Morris M, Kotton C, Wolfe C, editors. Emerging transplant infections. Cham: Springer International Publishing; 2020. p. 1-24. https://doi.org/10.1007/978-3-030-01751-4_40-1
31. Garnica M, Ramos JF, Machado CM. Endemic viral infections in immunocompromised hosts: dengue, chikungunya, zika. Curr Opin Infect Dis. 2024;37(4):238-44. https://doi.org/10.1097/QCO.0000000000001026
32. von Lilienfeld-Toal M, Khawaja F, Compagno F, Robin C, Piñana JL, Cesaro S, Einsele H, Ljungman P, Navarro D, Boeckh M, Chemaly RF, Hirsch HH. Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia. Lancet Infect Dis. 2026;26(3):E193-E206. https://doi.org/10.1016/S1473-3099(25)00365-2
33. Machado CM, Martins TC, Colturato I, Leite MS, Simione AJ, Souza MP, Mauad MA, Colturato VR. Epidemiology of neglected tropical diseases in transplant recipients. Review of the literature and experience of a Brazilian HSCT center. Rev Inst Med Trop S Paulo. 2009;51(6):309-24. https://doi.org/10.1590/S0036-46652009000600002
34. Adler M, Lapierre V, Sakr R, Bourhis JH, Gachot B, Castilla-Llorente C, Wyplosz B. Persistence of yellow
fever immunization–induced antibodies in allogeneic hematopoietic stem cell transplant recipients. J Infect Dis. 2018;217(11):1844-5. https://doi.org/10.1093/infdis/jiy050
35. Avelino-Silva VI, Freire MS, Rocha V, Rodrigues CA, Novis YS, Sabino EC, Kallas EG. Persistence of Yellow Fever vaccine-induced antibodies after cord blood stem cell transplant. Hum Vaccin Immunother. 2016;12(4):937-8. https://doi.org/10.1080/21645515.2015.1112475
36. Fontbrune FS, Arnaud C, Cheminant M, Boulay A, Konopacki J, Lapusan S, Robin C, Bernaudin F, Suarez F, Simon F, Socié G, Verdière NC, Consigny PH. Immunogenicity and safety of yellow fever vaccine in allogeneic hematopoietic stem cell transplant recipients after withdrawal of immunosuppressive therapy. J Infect Dis. 2018;217(3):494-7. https://doi.org/10.1093/infdis/jix564
37. Hayakawa K, Takasaki T, Tsunemine H, Kanagawa S, Kutsuna S, Takeshita N, Mawatari M, Fujiya Y, Yamamoto K, Ohmagari N, Kato Y. Persistent seropositivity for yellow fever in a previously vaccinated autologous hematopoietic stem cell transplantation recipient. Int J Infect Dis. 2015;37:9-10. https://doi.org/10.1016/j.ijid.2015.05.025
38. Testa LHA, Simione AJ, Santos ACF, Colturato I, Barbieri F, Souza MP, Colturato VR, Machado CM. Compliance with yellow fever and measles vaccines in the revaccination program post‐hematopoietic cell transplantation. Transpl Infect Dis. 2023;25(4):e14098. https://doi.org/10.1111/tid.14098
39. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161(4 Pt 2):S221-47. https://doi.org/10.1164/ajrccm.161.supplement_3.ats600
40. Rodrigues MO, Testa LHA, Santos ACF, Zanetti LP, Ruiz LS, Souza MP, Colturato VR, Machado CM. Latent and active tuberculosis infection in allogeneic hematopoietic stem cell transplant recipients: a prospective cohort study. Bone Marrow Transplant. 2021;56(9):2241-7. https://doi.org/10.1038/s41409-021-01329-3
41. Pinazo MJ, Miranda B, Rodríguez-Villar C, Altclas J, Serra MB, García-Otero EC, Almeida EA, García MM, Gascon J, Rodríguez MG, Manito N, Camacho AM, Oppenheimer F, Puente SP, Riarte A, Coronas JS, Lletí MS, Sanz GF, Torrico F, Tendero DT, Ussetti P, Shikanai-Yasuda MA. Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. Transplant Rev. 2011;25(3):91-101. https://doi.org/10.1016/j.trre.2010.12.002
42. Forsyth CJ, Manne-Goehler J, Bern C, Whitman J, Hochberg NS, Edwards M, Marcus R, Beatty NL, Castro-Sesquen YE, Coyle C, Granados PS, Hamer D, Maguire JH, Gilman RH, Meymandi S; US Chagas Diagnostic Working Group. Recommendations for screening and diagnosis of chagas disease in the United States. J Infect Dis. 2022;225(9):1601-10. https://doi.org/10.1093/infdis/jiab513
43. Prestes DP, Mendes C, Batista MV, Ramos JF, Schimidt Junior JS, Okay TS, Caiaffa H, Rocha VG, Costa SF. A case-series of toxoplasmosis in hematopoietic stem cell transplantation: still a concern for endemic countries. Bone Marrow Transplant. 2018;53(10):1336-9. https://doi.org/10.1038/s41409-018-0179-4
44. Aerts R, Mehra V, Groll AH, Martino R, Lagrou K, Robin C, Perruccio K, Blijlevens N, Nucci M, Slavin M, Bretagne S, Cordonnier C; European Conference on Infections in Leukaemia group. Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022. Lancet Infect Dis. 2024;24(5):e291-306. https://doi.org/10.1016/ S1473-3099(23)00495-4
45. Aerts R, Mercier T, Beckers M, Schoemans H, Lagrou K, Maertens J. Toxoplasmosis after allogeneic haematopoietic cell transplantation: experience using a PCR-guided pre-emptive approach. Clin Microbiol Infect. 2022;28(3):440-5. https://doi.org/10.1016/j.cmi.2021.09.033
46. Peixoto D, Prestes DP. Parasitic infections of the stem cell transplant recipient and the hematologic malignancy patient, including toxoplasmosis and strongyloidiasis. Infect Dis Clin North Am. 2019;33(2):567-91. https://doi.org/10.1016/j.idc.2019.02.009
47. Jarque I, Salavert M, Pemán J. Parasitic infections in hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis. 2016;8(1):1-15. https://doi.org/10.4084/MJHID.2016.035
48. Wickramasinghe SN, Abdalla SH. Blood and bone marrow changes in malaria. Best Pract Res Clin Haematol. 2000;13(2):277-99. https://doi.org/10.1053/beha.1999.0072
49. Inoue J, Machado CM, Lima GFMC, Nascimento MJC, Colturato VR, Santi SM. The monitoring of hematopoietic stem cell transplant donors and recipients from endemic areas for malaria. Rev Inst Med Trop S Paulo. 2010;52(5):281-4. https://doi.org/10.1590/S0036-46652010000500012
50. Mejia R, Booth GS, Fedorko DP, Hsieh MM, Khuu HM, Klein HG, Mu J, Fahle G, Nutman TB, Su XZ, Williams EC, Flegel WA, Klion A. Peripheral blood stem cell transplant-related Plasmodium falciparum infection in a patient with sickle cell disease. Transfusion. 2012;52(12):2677-82. https://doi.org/10.1111/j.1537-2995.2012.03673.x
51. O’Donnell J, Goldman JM, Wagner K, Ehinger G, Martin N, Leahy M, Kariuki N, Dokal I, Roberts I. Donorderived Plasmodium vivax infection following volunteer unrelated bone marrow transplantation. Bone Marrow Transplant. 1998;21(3):313-4. https://doi.org/10.1038/sj.bmt.1701073
52. Villeneuve L, Cassaing S, Magnaval JF, Boisseau M, Huynh A, Demur C, Calot JP. Plasmodium falciparum infection following allogeneic bone-marrow transplantation. Ann Trop Med Parasitol. 1999;93(5):533-5.
53. Wills BA, Nguyen MD, Ha TL, Dong TH, Tran TN, Le TT, Tran VD, Nguyen TH, Nguyen VC, Stepniewska K, White NJ, Farrar JJ. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med. 2005;353(9):877-89. https://doi.org/10.1056/nejmoa044057
54. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: Systematic review and meta-analysis. J Antimicrob Chemother. 2007;59(1):5-22. https://doi.org/10.1093/jac/dkl425
55. Wingard JR, Eldjerou L, Leather H. Use of antibacterial prophylaxis in patients with chemotherapy-induced neutropenia. Curr Opin Hematol. 2012;19(1):21-6. https://doi.org/10.1097/MOH.0b013e32834da9bf
56. Mikulska M, Cordonnier C. Fluoroquinolone prophylaxis during neutropenia: what can we expect nowadays? Clin Microbiol Infect. 2018;24(7):678-9. https://doi.org/10.1016/j.cmi.2018.02.031
57. Kimura M, Araoka H, Yoshida A, Yamamoto H, Abe M, Okamoto Y, Yuasa M, Kaji D, Kageyama K, Nishida A, Ishiwata K, Takagi S, Yamamoto G, Asano-Mori Y, Uchida N, Hishinuma A, Izutsu K, Wake A, Taniguchi S, Yoneyama A. Breakthrough viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients receiving levofloxacin prophylaxis in a Japanese hospital. BMC Infect Dis. 2016;16(1):372. https://doi.org/10.1186/s12879-016-1692-y
58. Signorelli J, Zimmer A, Liewer S, Shostrom VK, Freifeld A. Incidence of febrile neutropenia in autologous hematopoietic stem cell transplant (HSCT) recipients on levofloxacin prophylaxis. Transpl Infect Dis. 2020;22(2):e13225. https://doi.org/10.1111/tid.13225
59. Ricci E, Mesini A, Bandettini R, Faraci M, Castagnola E. Antibacterial prophylaxis of febrile neutropenia is not effective in the pre‐engraftment period in pediatric allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2020;22(5):e13340. https://doi.org/10.1111/tid.13340
60. Cordonnier C, Chevret S, Legrand M, Rafi H, Dhdin N, Lehmann B, Bassompierre F, Gluckman E. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? Ann Intern Med. 2003;139(1): 8-18. https://doi.org/10.7326/0003-4819-139-1-200307010-00007
61. Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients. Medicine. 2007;86(2):69-77. https://doi.org/10.1097/md.0b013e31803eb176
62. Reuter S, Kern WV, Sigge A, Dohner H, Marre R, Kern P, von Baum H. Impact of fluoroquinolone prophylaxis on reduced infection‐related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis. 2005;40(8):1087-93. https://doi.org/10.1086/428732
63. Yeshurun M, Vaxman I, Shargian L, Yahav D, Bishara J, Pasvolsky O, Wolach O, Lahav M, Gurion R, Magen H, Vidal L, Herscovici C, Peck A, Moshe M, Sela-Navon M, Naparstek E, Raanani P, Rozovski U. Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. Clin Microbiol Infect. 2018;24(7):749-54. https://doi.org/10.1016/j.cmi.2017.11.019
64. Alexander S, Fisher BT, Gaur AH, Dvorak CC, Villa Luna D, Dang H, Chen L, Green M, Nieder ML, Fisher B, Bailey LC, Wiernikowski J, Sung L; Children’s Oncology Group. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation. JAMA. 2018;320(10):995-1004. https://doi.org/10.1001/jama.2018.12512
65. Lehrnbecher T, Fisher BT, Phillips B, Alexander S, Ammann RA, Beauchemin M, Carlesse F, Castagnola E, Davis BL, Dupuis LL, Egan G, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, van de Wetering M, Wolf J, Cabral S, Robinson PD, Sung L. Guideline for antibacterial prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation. Clin Infect Dis. 2020;71(1):226-36. https://doi.org/10.1093/cid/ciz1082
66. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston KV, Strasfeld L, Flowers CR. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(30):3043-54. https://doi.org/10.1200/JCO.18.00374
67. Lindsay J, Yeoh D, Teh BW, Reynolds GK, Henden A, McQuilten Z, Wheeler M, Hamilton A, Nelson A, Nakagaki M, Sandhu S, Slavin MA; Australasian Neutropenic Fever Guidelines Steering Committee. Consensus guidelines for antibacterial prophylaxis in patients with neutropenia. Intern Med J. 2025;55(Suppl. 7): 115-35. https://doi.org/10.1111/imj.70250
68. Pittet D, Allegranzi B, Boyce J, World Health Organization World Alliance for Patient Safety First Global Patient Safety Challenge Core Group of Experts. The World Health Organization Guidelines on hand hygiene in health care and their consensus recommendations. Infect Control Hosp Epidemiol. 2009;30(7):611-22. https://doi.org/10.1086/600379
69. Morrisette T, Van Matre AG, Miller MA, Mueller SW, Bajrovic V, Abidi MZ, Benamu E, Kaiser JN, Barber GR, Chase S, Tobin J, Fish DN, Gutman JA. Oral vancomycin prophylaxis as secondary prevention against clostridioides difficile infection in the hematopoietic stem cell transplantation and hematologic malignancy population. Biol Blood Marrow Transplant. 2019;25(10):2091-7. https://doi.org/10.1016/j.bbmt.2019.06.021
70. Howell JE, Gulbis AM, Champlin RE, Qazilbash MH. Retrospective analysis of weekly intravenous immunoglobulin prophylaxis versus intravenous immunoglobulin by IgG level monitoring in hematopoietic stem cell transplant recipients. Am J Hematol. 2012;87(2):172-4. https://doi.org/10.1002/ajh.22229
71. Derman BA, Schlei Z, Parsad S, Mullane K, Knoebel RW. Changes in intravenous immunoglobulin usage for hypogammaglobulinemia after implementation of a stewardship program. JCO Oncol Pract. 2020;17(3):e445-e453. https://doi.org/10.1200/OP.20.00312
72. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335-47. https://doi.org/10.1056/nejmoa061098
73. Lehrnbecher T, Fisher BT, Phillips B, Beauchemin M, Carlesse F, Castagnola E, Duong N, Dupuis LL, Fioravantti V, Groll AH, Haeusler GM, Roilides E, Science M, Steinbach WJ, Tissing W, Warris A, Patel P, Robinson PD, Sung L. Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. J Clin Oncol. 2020;38(27):3205-16. https://doi.org/10.1200/JCO.20.00158
74. Garcia‐Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47(8):1041-50. https://doi.org/10.1086/591969
75. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo‐controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis. 1999;28(2):331-40. https://doi.org/10.1086/515128
76. Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, Miller PJS, Ribaud P, Schlamm HT, Solano C, Cook G; IMPROVIT Study Group. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem‐cell transplantation. Br J Haematol. 2011;155(3):318-27. https://doi.org/10.1111/j.1365-2141.2011.08838.x
77. Park S, Kim K, Jang JH, Kim SJ, Kim WS, Chung DR, Kang CI, Peck KR, Jung CW. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. J Infection. 2016;73(5):496-505. https://doi.org/10.1016/j.jinf.2016.06.011
78. Huang X, Chen H, Han M, Zou P, Wu D, Lai Y, Huang H, Chen X, Liu T, Zhu H, Wang J, Hu J. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Biol Blood Marrow Transpl. 2012;18(10):1509-16. https://doi.org/10.1016/j.bbmt.2012.03.014
79. van Burik JAH, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407-16. https://doi.org/10.1086/422312
80. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL, Maziarz RT, Stadtmauer EA, Bolaños-Meade J, Brown J, DiPersio JF, Boeckh M, Marr KA; Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111-8. https://doi.org/10.1182/blood-2010-02-268151
81. Erard V, Guthrie K, Varley C, Heugel J, Wald A, Flowers MED, Corey L, Boeckh M. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood. 2007;110(8):3071-7. https://doi.org/10.1182/blood-2007-03-077644
82. Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35(11):1065-9. https://doi.org/10.1038/sj.bmt.1704959
83. Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA, Leavitt RY, Badshah C. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. New Engl J Med. 2017;377(25):2433-44. https://doi.org/10.1056/NEJMoa1706640
84. Russo D, Schmitt M, Pilorge S, Stelljes M, Kawakita T, Teal VL, Haber B, Bopp C, Dadwal SS, Badshah C. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stemcell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2024;11(2):e127-35. https://doi.org/10.1016/S2352-3026(23)00344-7
85. Ljungman P, Alain S, Chemaly RF, Einsele H, Galaverna F, Hirsch HH, Sadowska-Klasa A, Navarro D, Styczynski J, Camara R. Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies. Lancet Infect Dis. 2025;25(8):e451-62. https://doi.org/10.1016/S1473-3099(25)00069-6
86. Vendemini F, Lorenzo P, Romani F, Malandrin SMI, Verna M, Bonanomi S, Valsecchi MG, Lucchini G, Balduzzi A. Letermovir primary and secondary prophylaxis in pediatric recipients of allogeneic haematopoietic stem cell transplant. Transplant Cell Ther. 2025;31(9):699.e1-e11. https://doi.org/10.1016/j.jtct.2025.05.021
87. Zhu Y, Wang L, Xiang Y, Wang Y, Zhang A, Wang Y, Yin M, Dun J, Xu Y, Hu Q, Yu W, Liu A. Efficacy and safety of letermovir for cytomegalovirus prophylaxis following allogeneic hematopoietic stem cell transplantation in pediatric patients. Drug Des Devel Ther. 2025;19:5059-69. https://doi.org/10.2147/DDDT.S513383
88. Groll AH, Danziger-Isakov L, Gefen A, Fraser CJ, Schulte JH, Bielorai B, Karras NA, Bueno D, Shaw PJ, Broyde N, Haber B, Gilbert CL, Patel M, McCrea JB, Badshah C. Cytomegalovirus prophylaxis with letermovir in pediatric (birth to <18 years of age) hematopoietic cell transplant recipients: pharmacokinetics, efficacy, and safety results of a Phase 2b study. Antimicrob Agents Chemother. 2025;69(10):e00420-25. https://doi.org/10.1128/aac.00420-25
89. Sarmati L, Andreoni M, Antonelli G, Arcese W, Bruno R, Coppola N, Gaeta GB, Galli M, Girmenia C, Mikulska M, Pane F, Perno CF, Picardi M, Puoti M, Rambaldi A, Svicher V, Taliani G, Gentile G. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper. Clin Microbiol Infect. 2017;23(12):935-40. https://doi.org/10.1016/j.cmi.2017.06.023
90. Furfaro E, Nicolini L, Della Vecchia A, Di Grazia C, Raiola AM, Varaldo R, Ferrando F, Barisione G, Bruzzone B, Angelucci E, Viscoli C, Mikulska M. Hepatitis E virus infection in an italian cohort of hematopoietic stem cell transplantation recipients: seroprevalence and infection. Biol Blood Marrow Transplant. 2020;26(7):1355-62. https://doi.org/10.1016/j.bbmt.2020.03.012
91. Damiris K, Meybodi MA, Niazi M, Pyrsopoulos N. Hepatitis E in immunocompromised individuals. World J Hepatol. 2022;14(3):482-94. https://doi.org/10.4254/wjh.v14.i3.482
92. Swartling L, Nordén R, Samuelsson E, Boriskina K, Valentini D, Westin J, Norder H, Sparrelid E, Ljungman P. Hepatitis E virus is an infrequent but potentially serious infection in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2020;55(7):1255-63. https://doi.org/10.1038/s41409-020-0823-7
93. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European conference on infections in leukaemia (ECIL-4): Guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis. 2013;56(2):258-66. https://doi.org/10.1093/cid/cis844
94. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG; Oseltamivir Study Group. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. New Engl J Med. 1999;341(18):1336-43. https://doi.org/10.1056/NEJM199910283411802
95. Lunde LE, Dasaraju S, Cao Q, Cohn CS, Reding M, Bejanyan N, Trottier B, Rogosheske J, Brunstein C, Warlick E, Young JAH, Weisdorf DJ, Ustun C. Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival. Bone Marrow Transplant. 2015;50(11):1432-7. https://doi.org/10.1038/bmt.2015.162
96. Cesaro S, Dalianis T, Hanssen Rinaldo C, Koskenvuo M, Pegoraro A, Einsele H, Cordonnier C, Hirsch HH; ECIL-6 Group. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2018;73(1):12-21. https://doi.org/10.1093/jac/dkx324
97. Yang A, Shi J, Luo Y, Ye Y, Tan Y, Huang H, Zhao Y. Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis. Sci Rep. 2019;9(1):20402. https://doi.org/10.1038/s41598-019-56013-w
98. Lee HJ, Lee DG, Choi SM, Park SH, Cho SY, Choi JK, Kim SH, Choi JH, Yoo JH, Cho BS, Eom KS, Lee S, Kim YJ, Kim HJ, Min CK, Kim DW, Lee JW, Min WS, Jung JI. The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population. PLoS One. 2017;12(3):e0173250. https://doi.org/10.1371/journal.pone.0173250
99. Brasil. Protocolo de vigilância da infecção latente pelo Mycobacterium tuberculosis no Brasil [Internet]. 2ª ed. Brasília, DF: Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis; 2022 [cited 2025 Nov 11]. Available from: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/svsa/tuberculose/protocolo-devigilancia-da-infeccao-latente-pelo-mycobacterium-tuberculosis-no-brasil.pdf
100. Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, Hauser PM, Lagrou K, Melchers WJG, Helweg-Larsen J, Matos O, Bretagne S, Cordonnier C; 5th European Conference on Infections in Leukaemia (ECIL-5). ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):2397-404. https://doi.org/10.1093/jac/dkw157
101. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40(12):1762-9. https://doi.org/10.1086/429921
102. Nouer SA, Nucci M, Kumar NS, Grazziutti M, Barlogie B, Anaissie E. Earlier response assessment in invasive Aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis. 2011;53(7):671-6. https://doi.org/10.1093/cid/cir441
103. Girmenia C, Micozzi A, Gentile G, Santilli S, Arleo E, Cardarelli L, Capria S, Minotti C, Cartoni C, Brocchieri S, Guerrisi V, Meloni G, Foà R, Martino P. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol. 2010;28(4):667-74. https://doi.org/10.1200/JCO.2009.21.8032
104. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J,
Boogaerts M, Van Eldere J. Galactomannan and computed tomography-based preemptive antifungal
therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41(9):1242-50. https://doi.org/10.1086/496927
105. Nucci M, Nouér SA, Grazziutti M, Kumar NS, Barlogie B, Anaissie E. Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis. 2010;51(11):1273–80. https://doi.org/10.1086/657065
106. Nucci M, Nouer SA, Cappone D, Anaissie E. Early diagnosis of invasive pulmonary aspergillosis in hematologic patients: an opportunity to improve the outcome. Haematologica. 2013;98(11):1657-60. https://doi.org/10.3324/haematol.2013.094359
107. Miceli MH, Grazziutti ML, Woods G, Zhao W, Kocoglu MH, Barlogie B, Anaissie E. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis. 2008;46(9):1412-22. https://doi.org/10.1086/528714
108. Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, Hubacek P, Navarro D, Cordonnier C, Ward KN; 2017 European Conference on Infections in Leukaemia group. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260-72. https://doi.org/10.1016/S1473-3099(19)30107-0
109. Styczynski J, van der Velden W, Fox CP, Engelhard D, Camara R, Cordonnier C, Ljungman P; Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101(7):803-11. https://doi.org/10.3324/haematol.2016.144428
110. Souza ABC, Simione AJ, Santos ACF, Colturato I, Barbieri FR, Moreno JRP, Zanetti LP, Oliveira LCS, Delattre ERP, Santos JS, Souza MP, Colturato VAR, Machado CM. Preemptive rituximab for Epstein–Barr virus reactivation after hematopoietic cell transplantation: necessary for all? Transpl Infect Dis. 2025;28(1):e70124. https://doi.org/10.1111/tid.70124
111. Ward KN, Hill JA, Hubacek P, Camara R, Crocchiolo R, Einsele H, Navarro D, Robin C, Cordonnier C, Ljungman P; 2017 European Conference on Infections in Leukaemia (ECIL). Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation. Haematologica. 2019;104(11):2155-63. https://doi.org/10.3324/haematol.2019.223073
112. Noviello M, Lorentino F, Xue E, Racca S, Furnari G, Valtolina V, Campodonico E, Dvir R, Lupo Stanghellini MT, Giglio F, Piemontese S, Clerici D, Oltolini C, Tassi E, Beretta V, Farina F, Mannina D, Ardemagni A, Vago L, Bernardi M, Corti C, Peccatori J, Clementi M, Ciceri F, Bonini C, Greco R. Human herpesvirus 6–specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients. Blood Adv. 2023;7(18): 5446-57. https://doi.org/10.1182/bloodadvances.2022009274
113. Perruccio K, Ward KN, Tridello G, Knelange N, Zeiser R, Franke GN, Sirvent A, Einsele H, Vicent MG, Navarro JMF, Contentin N, Collin M, Martino R, Gambella M, Sengeloev H, Passweg J, Snowden J, Nagler A, Kulagin A, Gabriel M, Kröger N, Pascual Cascon MJ, Yeshurun M, Güngör T, Robin C, Clark A, Duarte ML, Amor AA, Itala-Remes M, Mikulska M, Styczynski J, Camara R, Ljungman P, Averbuch D, Cesaro S. Clinical characteristic and outcome of HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: A study of Infectious Disease Working Party of EBMT. Bone Marrow Transplant. 2025;60(9):1243-8. https://doi.org/10.1038/s41409-025-02638-7
114. Styczynski J, Tridello G, Knelange N, Wendel L, Ljungman P, Mikulska M, Gil L, Cesaro S, Averbuch D, von dem Borne P, Xhaard A, Mielke S, Neven B, Snowden JA, Dalle JH, Rubio MT, Crawley C, Maertens J, Kuball J, Chevallier P, Michel G, Gabriel M, Burns D, Wynn RF, Renard C, Blijlevens N, Jubert C, Gedde-Dahl T, Collin M, Labussiere-Wallet H, Kalwak K, Broers AEC, Yakoub-Agha I, Itäla-Remes M, Camara R. Adenovirus infections after allogeneic hematopoietic cell transplantation in children and adults: a study from the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2024;59(10):1402-12. https://doi.org/10.1038/s41409-024-02361-9
115. Giménez E, Piñana JL, Albert E, Torres I, Pérez A, Hernández-Boluda JC, Solano C, Navarro D. Adenovirus burden in allogeneic hematopoietic stem cell transplantation: monitoring versus symptoms‐based testing—a cost‐effectiveness analysis. Transpl Infect Dis. 2025;27(5):e70089. https://doi.org/10.1111/tid.70089
116. Matthes-Martin S, Feuchtinger T, Shaw PJ, Engelhard D, Hirsch HH, Cordonnier C, Ljungman P; Fourth European Conference on Infections in Leukemia. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: Summary of ECIL-4 (2011). Transpl Infect Dis. 2012;14(6):555-63. https://doi.org/10.1111/tid.12022
117. Brasil. Guia de manejo clínico da infecção pelo HTLV [Internet]. Brasília, DF: Ministério da Saúde, Secretaria de Vigilância em Saúde; 2021 [cited 2026 July 28]. Available from: https://portal.saude.sp.gov.br/resources/crt/eventos/materiais-tecnicos/htlv/guia_htlv_internet_24.11.21-2_31.pdf?attach=true
118. Machado, C., Carnaval, A. G., Mauad, M., Ferrari dos Santos, A. C., Simione, A. J., de Souza, A. B. C., Colturato, I., Barbieri, F. R., Zanetti, L. P., Serra, L. de O., Vicari, J. do P. M., Dellatre, E. R. P., Mascarenhas, C. F., Augusto, G., de Souza, M. P., & Colturato, V. A. R. (2024). Prevalence of Trypanosoma cruzi infection and frequency of reactivation in hematopoietic cell transplantation. Retrospective single-center study. Journal of Bone Marrow Transplantation and Cellular Therapy, 5(suppl1), 95–96. https://jbmtct.sbtmo.org.br/jbmtct/
issue/view/21
119. Pierrotti LC, Levi ME, Di Santi SM, Segurado AC, Petersen E. Malaria disease recommendations for solid organ transplant recipients and donors. Transplantation. 2018;102(2S):S16-26. https://doi.org/10.1097/TP.0000000000002017
120. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, Carlesse F, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, Castagnola E, Davis BL, Dupuis LL, Gaur AH, Tissing WJE, Zaoutis T, Phillips R, Sung L. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol. 2017;35(18):2082–94. https://doi.org/10.1200/JCO.2016.71.7017
121. Nucci M, Arrais-Rodrigues C, Bergamasco MD, Garnica M, Gloria ABF, Guarana M, Machado C, Ramos J, Salvino MA, Simões B. Management of febrile neutropenia: consensus of the Brazilian Association of Hematology, Blood Transfusion and Cell Therapy - ABHH. Hematol Transfus Cell Ther. 2024;46(Suppl. 6): S346-61. https://doi.org/10.1016/j.htct.2024.11.119
122. Bow EJ, Rotstein C, Noskin GA, Laverdière M, Schwarer AP, Segal BH, Seymour JF, Szer J, Sanche S. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillintazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis. 2006;43(4):447-59. https://doi.org/10.1086/505393
123. Aguilar-Guisado M, Espigado I, Martín-Peña A, Gudiol C, Royo-Cebrecos C, Falantes J, Vázquez-López L, Montero MI, Rosso-Fernández C, Martino ML, Parody R, González-Campos J, Garzón-López S, Calderón-Cabrera C, Barba P, Rodríguez N, Rovira M, Montero-Mateos E, Carratalá J, Pérez-Simón JA, Cisneros JM. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol. 2017;4(12):e573-83. https://doi.org/10.1016/S2352-3026(17)30211-9
124. Hayase E, Hayase T, Jamal MA, Miyama T, Chang CC, Ortega MR, Ahmed SS, Karmouch JL, Sanchez CA, Brown AN, El-Himri RK, Flores II, McDaniel LK, Pham D, Halsey T, Frenk AC, Chapa VA, Heckel BE, Jin Y, Tsai WB, Prasad R, Tan L, Veillon L, Ajami NJ, Wargo JA, Galloway-Peña J, Shelburne S, Chemaly RF, Davey L, Glowacki RWP, Liu C, Rondon G, Alousi AM, Molldrem JJ, Champlin RE, Shpall EJ, Valdivia RH, Martens EC, Lorenzi PL, Jenq RR. Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease. Cell. 2022;185(20):3705-3719.e14. https://doi.org/10.1016/j.cell.2022.09.007
125. Beyar-Katz O, Dickstein Y, Borok S, Vidal L, Leibovici L, Paul M. Empirical antibiotics targeting grampositive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev. 2017;2017(6):CD003914. https://doi.org/10.1002/14651858.CD003914.pub4
126. Chumbita M, Puerta-Alcalde P, Gudiol C, Garcia-Pouton N, Laporte-Amargós J, Ladino A, Albasanz-
Puig A, Helguera C, Bergas A, Grafia I, Sastre E, Suárez-Lledó M, Durà X, Jordán C, Marco F, Condom M, Castro P, Martínez JA, Mensa J, Soriano A, Carratalà J, Garcia-Vidal C. 2022. Impact of empirical antibiotic regimens on mortality in neutropenic patients with bloodstream infection presenting with septic shock. Antimicrob Agents Chemother. 2022;66:e01744-21. https://doi.org/10.1128/AAC.01744-21
127. Guarana M, Nucci M, Nouér SA. Shock and early death in hematologic patients with febrile neutropenia. Antimicrob Agents Chemother. 2019;63(11):10.1128/aac.01250-19. https://doi.org/10.1128/AAC.01250-19
128. Martinez-Nadal G, Puerta-Alcalde P, Gudiol C, Cardozo C, Albasanz-Puig A, Marco F, Laporte Amargós J, Moreno-García E, Domingo-Doménech E, Chumbita M, Martínez JA, Soriano A, Carratalà J, Garcia-Vidal C. Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance. Clin Infect Dis. 2020;70(6):1068-74. https://doi.org/10.1093/cid/ciz319
129. Forcina A, Lorentino F, Marasco V, Oltolini C, Marcatti M, Greco R, Lupo-Stanghellini MT, Carrabba M, Bernardi M, Peccatori J, Corti C, Ciceri F. Clinical impact of pretransplant multidrug-resistant gramnegative colonization in autologous and allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(7):1476-82. https://doi.org/10.1016/j.bbmt.2018.02.021
130. Cattaneo C, Di Blasi R, Skert C, Candoni A, Martino B, Di Renzo N, Delia M, Ballanti S, Marchesi F, Mancini V, Orciuolo E, Cesaro S, Prezioso L, Fanci R, Nadali G, Chierichini A, Facchini L, Picardi M, Malagola M, Orlando V, Trecarichi EM, Tumbarello M, Aversa F, Rossi G, Pagano L; SEIFEM Group. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria. Ann Hematol. 2018;97(9):1717-26. https://doi.org/10.1007/s00277-018-3341-6
131. Cámara R, Figuera A, Sureda A, Hermida G, Verge G, Olalla I, Rañada JMF, Albos AD. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study. Haematologica. 1997;82(6):668-75.
132. Hazel DL, Graham J, Dickinson JP, Newland AC, Kelsey SM. Piperacillin-tazobactam as empiric monotherapy in febrile neutropenic patients with haematological malignancies. J Chemother. 1997;9(4):267-72. https://doi.org/10.1179/joc.1997.9.4.267
133. Erjavec Z, Vries-Hospers HG, Laseur M, Halie RM, Daenen S. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother. 2000;45(6):843-9. https://doi.org/10.1093/jac/45.6.843
134. Cometta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, Korten V, Vandercam M, Gaya H, Padmos A, Klastersky J, Zinner S, Glauser MP, Calandra T, Viscoli C; International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003;37(3):382-9. https://doi.org/10.1086/376637
135. Rosa RG, Santos RP, Goldani LZ. Comparison of anti-anaerobic antimicrobial strategies in cancer patients with febrile neutropenia and gastrointestinal symptoms. BMC Res Notes. 2014;7(1):614. https://doi.org/10.1186/1756-0500-7-614
136. Sachak T, Arnold MA, Naini BV, Graham RP, Shah SS, Cruise M, Park JY, Clark L, Lamps L, Frankel WL, Theodoropoulos N, Arnold CA. Neutropenic enterocolitis. Am J Surg Pathol. 2015;39(12):1635-42. https://doi.org/10.1097/PAS.0000000000000517
137. Gustinetti G, Raiola AM, Varaldo R, Galaverna F, Gualandi F, Del Bono V, Bacigalupo A, Angelucci E, Viscoli C, Mikulska M. De-escalation and discontinuation of empirical antibiotic treatment in a cohort of allogeneic hematopoietic stem cell transplantation recipients during the pre-engraftment period. Biol Blood Marrow Transpl. 2018;24(8):1721-6. https://doi.org/10.1016/j.bbmt.2018.03.018
138. Rearigh L, Stohs E, Freifeld A, Zimmer A. De-escalation of empiric broad spectrum antibiotics in hematopoietic stem cell transplant recipients with febrile neutropenia. Ann Hematol. 2020;99(8):1917-24. https://doi.org/10.1007/s00277-020-04132-0
139. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72(1):101-11. https://doi.org/10.1016/0002-9343(82)90594-0
140. Maertens J, Lodewyck T, Donnelly JP, Chantepie S, Robin C, Blijlevens N, Turlure P, Selleslag D, Baron F, Aoun M, Heinz WJ, Bertz H, Ráčil Z, Vandercam B, Drgona L, Coiteux V, Llorente CC, Schaefer-Prokop C, Paesmans M, Ameye L, Meert L, Cheung KJ, Hepler DA, Loeffler J, Barnes R, Marchetti O, Verweij P, Lamoth F, Bochud PY, Schwarzinger M, Cordonnier C; Infectious Diseases Group and the Acute Leukemia Group of the European Organization for Research and Treatment of Cancer. Empiric vs preemptive antifungal strategy in high-risk neutropenic patients on fluconazole prophylaxis: a randomized trial of the European Organization for Research and Treatment of Cancer. Clin Infect Dis. 2023;76(4):674-82. https://doi.org/10.1093/cid/ciac623
141. Santolaya ME, Alvarez AM, Acuña M, Avilés CL, Salgado C, Tordecilla J, Varas M, Venegas M, Villarroel M, Zubieta M, Farfán M, Maza V, Vergara A, Valenzuela R, Torres JP. Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial. J Antimicrob Chemother. 2018;73(10):2860-6. https://doi.org/10.1093/jac/dky244
142. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med. 1989;86(6):668-72. https://doi.org/10.1016/0002-9343(89)90441-5
143. Papanicolaou GA, Avery RK, Cordonnier C, Duarte RF, Haider S, Maertens J, Peggs KS, Solano C, Young JAH, Fournier M, Murray RA, Wu J, Winston DJ; AURORA Trial Investigators. Treatment for first cytomegalovirus infection post–hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir. Clin Infect Dis. 2024;78(3):562-72. https://doi.org/10.1093/cid/ciad709
144. Khawaja F, Zamora D, Yong MK, Hakki M, Goscicki BK, Danziger-Isakov L, Lin A, Carpenter PA, Boeckh M, Papanicolaou GA, Dadwal SS, Chemaly RF. American Society for Transplantation and Cellular Therapy Series #11: updated cytomegalovirus guidelines in hematopoietic cell transplant and cellular therapy recipients. Transplant Cell Ther. 2025;31(10):727-41. https://doi.org/10.1016/j.jtct.2025.06.025
145. Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HAH, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S; German PTLD Study Group; European PTLD Network. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13(2):196-206. https://doi.org/10.1016/S1470-2045(11)70300-X
146. Handley G. Current role of prospective monitoring and preemptive and prophylactic therapy for human herpesvirus 6 after allogeneic stem cell transplantation. Open Forum Infect Dis. 2022;9(8):ofac398. https://doi.org/10.1093/ofid/ofac398
147. Tatarelli P, Mikulska M. Multidrug-resistant bacteria in hematology patients: emerging threats. Future Microbiol. 2016;11(6):767-80. https://doi.org/10.2217/fmb-2015-0014
148. Rashidi A, Ebadi M, Rehman TU, Elhusseini H, Kazadi D, Halaweish H, Khan MH, Hoeschen A, Cao Q, Luo X, Kabage AJ, Lopez S, Holtan SG, Weisdorf DJ, Khoruts A, Staley C. Randomized double-blind phase II trial of fecal microbiota transplantation versus placebo in allogeneic hematopoietic cell transplantation and AML. J Clin Oncol. 2023;41(34):5306-19. https://doi.org/10.1200/JCO.22.02366
149. Stabholz Y, Paul M. The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis. Clin Microbiol Infect. 2024;30(1):51-8. https://doi.org/10.1016/j.cmi.2023.09.002
150. Piekarska A, Sadowska-Klasa A, Mensah-Glanowska P, Sobczyk-Kruszelnicka M, Drozd-Sokołowska J, Waszczuk-Gajda A, Kujawska J, Wilk M, Tomaszewska A, Zaucha JM, Giebel S, Gil L. Effective treatment of Clostridioides difficile infection improves survival and affects graft-versus-host disease: a multicenter study by the Polish Adult Leukemia Group. Sci Rep. 2024;14(1):5947. https://doi.org/10.1038/s41598-024-56336-3
151. Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, Krüger W, Mousset S, Neuburger S, Neumann S, Penack O, Silling G, Vehreschild JJ, Einsele H, Maschmeyer G; Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO); DAG-KBT (German Working Group for Blood and Marrow Transplantation). Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol. 2016;95(9):1435-55. https://doi.org/10.1007/s00277-016-2711-1
152. Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4): 1-187. https://doi.org/10.15585/mmwr.rr7004a1
153. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, Pauw B; Invasive Fungal Infections Group of the European Organization for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-15. https://doi.org/10.1056/nejmoa020191
154. Maertens JA, Rahav G, Lee DG, Ponce-de-León A, Ramírez Sánchez IC, Klimko N, Sonet A, Haider S, Vélez JD, Raad I, Koh LP, Karthaus M, Zhou J, Ben-Ami R, Motyl MR, Han S, Grandhi A, Waskin H; study investigators. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. The Lancet. 2021;397(10273):499-509. https://doi.org/10.1016/S0140-6736(21)00219-1
155. Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. The Lancet. 2016;387(10020):760-9. https://doi.org/10.1016/S0140-6736(15)01159-9
156. Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Ráčil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JAH, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJGT; VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7): 828-37. https://doi.org/10.1016/S1473-3099(16)00071-2
157. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B–based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503-9. https://doi.org/10.1086/590004
158. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-53. https://doi.org/10.1086/432579
159. Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect. 2016;22(9):811.e1-e8. https://doi.org/10.1016/j.cmi.2016.03.029
160. Nucci M, Marr KA, Vehreschild MJ, de Souza CA, Velasco E, Cappellano P, Carlesse F, Queiroz-Telles F, Sheppard DC, Kindo A, Cesaro S, Hamerschlak N, Solza C, Heinz WJ, Schaller M, Atalla A, Arikan-Akdagli S, Bertz H, Galvão Castro C Jr, Herbrecht R, Hoenigl M, Härter G, Hermansen NE, Josting A, Pagano L, Salles MJ, Mossad SB, Ogunc D, Pasqualotto AC, Araujo V, Troke PF, Lortholary O, Cornely OA, Anaissie E. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect. 2014;20(6): 580-5. https://doi.org/10.1111/1469-0691.12409
161. Bandeira TFGS, Marti LC, Rother ET, Correia LR, Machado CM. Use of specific T lymphocytes in treating cytomegalovirus infection in hematopoietic cell transplant recipients: a systematic review. Pharmaceutics. 2024;16(10):1321. https://doi.org/10.3390/pharmaceutics16101321
162. Dominietto A, Tedone E, Soracco M, Bruno B, Raiola AM, Van Lint MT, Geroldi S, Lamparelli T, Galano B, Gualandi F, Frassoni F, Bacigalupo A. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant. 2012;47(1):101-6. https://doi.org/10.1038/bmt.2011.28
163. Hill JA. Human herpesvirus 6 in transplant recipients. Curr Opin Infect Dis. 2019;32(6):584-90. https://doi.org/10.1097/QCO.0000000000000592
164. Machado CM, Boas LSV, Mendes AVA, Rocha IF, Sturaro D, Dulley FL, Pannuti CS. Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant. 2004;34(2):111-4. https://doi.org/10.1038/sj.bmt.1704534
165. Khawaja F, Chemaly RF. Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies. Haematologica. 2019;104(7):1322-31. https://doi.org/10.3324/haematol.2018.215152
166. Sim SA, Leung VKY, Ritchie D, Slavin MA, Sullivan SG, Teh BW. Viral respiratory tract infections in allogeneic hematopoietic stem cell transplantation recipients in the era of molecular testing. Biol Blood Marrow Transplant. 2018;24(7):1490-6. https://doi.org/10.1016/j.bbmt.2018.03.004
167. Bhimraj A, Morgan RL, Shumaker AH, Baden LR, Cheng VCC, Edwards KM, Gallagher JC, Gandhi RT, Muller WJ, Nakamura MM, O’Horo JC, Shafer RW, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022). Clin Infect Dis. 2024;78(7):e250-e349. https://doi.org/10.1093/cid/ciac724
168. Cesaro S, Ljungman P, Mikulska M, Hirsch HH, Navarro D, Cordonnier C, Mehra V, Styczynski J, Marchesi F, Piñana JL, Beutel G, Einsele H, Maertens J; ECIL-10; de la Camara R. Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10). Leukemia. 2025;39(9): 2061-71. https://doi.org/10.1038/s41375-025-02649-9
169. Hijano DR, Ferrolino JA, Hidinger J, Brazelton JN, Gu Z, Suganda S, Glasgow HL, Allison KJ, Peterson M, Dallas RH, Maron G, Hayden RT. Clinical correlation of adenoviral load in the respiratory tract measured by digital PCR in immunocompromised children. Open Forum Infect Dis. 2023;10(2):ofad030. https://doi.org/10.1093/ofid/ofad030
170. Batista MV, El Chaer F, Englund JA, Boeckh M, Carpenter PA, Dadwal SS, Waghmare A, Navarro D, Hirsch HH, Piñana JL, Papanicolaou GA, Chemaly RF. American Society for Transplantation and Cellular Therapy Series #10: management of parainfluenza and human metapneumovirus infections in hematopoietic cell transplantation and cellular therapy recipients. Transplant Cell Ther. 2025;31(9):624-38. https://doi.org/10.1016/j.jtct.2025.06.016
171. Costa SF, Ramos JF, Batista MV. Tuberculosis in hematopoietic stem cell transplant recipients. Mediterr J Hematol Infect Dis. 2013;5(1):e2013061. https://doi.org/10.4084/mjhid.2013.061
172. Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P; 6th European Conference on Infections in Leukemia (ECIL-6). ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother. 2016;71(9):2405-13. https://doi.org/10.1093/jac/dkw158
173. Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, Lavallade H, Gallo G, Lehrnbecher T, Engelhard D, Ljungman P; European Conference on Infections in Leukaemia group. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(6):e200-12. https://doi.org/10.1016/S1473-3099(18)30600-5
174. Ambati A, Boas LSV, Ljungman P, Testa L, de Oliveira JF, Aoun M, Colturato V, Maeurer M, Machado CM. Evaluation of pretransplant influenza vaccination in hematopoietic SCT: A randomized prospective study. Bone Marrow Transplant. 2015;50(6):858-64. https://doi.org/10.1038/bmt.2015.47
175. Adati EM, da Silva PM, Sumita LM, Rodrigues MO, Zanetti LP, Santos ACF, Souza MP, Colturato VR, Machado CM. Poor response to hepatitis A vaccination in hematopoietic stem cell transplant recipients. Transplant Infect Dis. 2020;22(3):e13258. https://doi.org/10.1111/tid.13258
176. Machado CM, Souza VAUF, Sumita LM, Rocha IF, Dulley FL, Pannuti CS. Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant. 2005;35(8):787-91. https://doi.org/10.1038/sj.bmt.1704878
177. Sociedade Brasileira de Imunização. Calendário de vacinação de pacientes especiais [Internet]. Sociedade Brasileira de Imunização; 2025 [cited 2025 Nov 17]. Available from: https://sbim.org.br/images/calendvacinacao-pacientes-especiais-2025-250821.pdf_2025-08-21.pdf
178. Bastidas A, Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, Gaidano G, Lee JJ, Abhyankar S, Solano C, Oteyza JP, Satlin MJ, Schwartz S, Campins M, Rocci A, Vallejo Llamas C, Lee DG, Tan SM, Johnston AM, Grigg A, Boeckh MJ, Campora L, Lopez-Fauqued M, Heineman TC, Stadtmauer EA, Sullivan KM; ZOE-HSCT Study Group Collaborators. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123-33. https://doi.org/10.1001/jama.2019.9053
179. Hall VG, Alexander AA, Mavandadnejad F, Kern-Smith M, Dang X, Kang R, Humar S, Winichakoon P, Johnstone R, Aversa M, Novitzky-Basso I, Lavoie PM, Kumar D, Mattsson J, Ferreira VH. Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: An Interventional Cohort Study. Clin Microbiol Infect. 2026;32(1):161-8. https://doi.org/10.1016/j.cmi.2025.09.013
180. Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D; AReSVi-006 Study Group. Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clin Infect Dis. 2024;78(6):1732-44. https://doi.org/10.1093/cid/ciae010
181. Koldehoff M, Horn PA, Lindemann M. Cellular immune response after vaccination with an adjuvanted, recombinant zoster vaccine in allogeneic hematopoietic stem cell transplant recipients. Vaccines. 2022;10(5):809. https://doi.org/10.3390/vaccines10050809
182. Provost-Olewczynska JX, Eberhardt CS. Adjuvanted recombinant zoster vaccine in solid organ transplant and hematopoietic stem-cell transplant recipients. Curr Opin Infect Dis. 2022;35(4):312-20. https://doi.org/10.1097/QCO.0000000000000845
183. Reynolds G, Hall VG, Teh BW. Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy. Transplant Infectious Disease. 2023;25(Suppl. 1):e14109. https://doi.org/10.1111/tid.14109
184. Randi BA, Fernandes EG, Higashino HR, Lopes MH, Rocha VG, Costa SF, Sartori AMC. Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation. Rev Inst Med Trop S Paulo. 2023;65:e21. https://doi.org/10.1590/S1678-9946202365021
185. Groeneweg L, Loeffen YGT, Versluys AB, Wolfs TFW. Safety and efficacy of early vaccination with live attenuated measles vaccine for hematopoietic stem cell transplant recipients and solid organ transplant recipients. Vaccine. 2021;39(25):3338-45. https://doi.org/10.1016/j.vaccine.2021.04.049
186. Nishikawa K, Kimura K, Kanda Y, Sugiyama M, Kakihana K, Doki N, Ohashi K, Bae SK, Takahashi K, Ishihara Y, Mizuno I, Onishi Y, Onozawa M, Onizuka M, Yamamoto M, Ishikawa T, Inoue K, Kusumoto S, Hashino S, Saito H, Kanto T, Sakamaki H, Mizokami M. A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020;55(7):1388-98. https://doi.org/10.1038/s41409-020-0833-5
187. Baumrin E, Izaguirre NE, Bausk B, Feeley MM, Bay CP, Yang Q, Ho VT, Baden LR, Issa NC. Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation. Blood Adv. 2021;5(6):1585-93. https://doi.org/10.1182/bloodadvances.2020003749
188. Karakulska-Prystupiuk E, Feliksbrot-Bratosiewicz M, Król M, Tomaszewska A, Jędrzejczak WW, Basak GW. Prevalence of VZV reactivation and effectiveness of vaccination with recombinant adjuvanted zoster vaccine in allogeneic hematopoietic stem cell recipients—a single-center analysis. Infect Dis Rep. 2025;17(3):48. https://doi.org/10.3390/idr17030048
189. Kallás EG, Cintra MAT, Moreira JA, Patiño EG, Braga PE, Tenório JCV, Infante V, Palacios R, Lacerda MVG, Pereira DB, Fonseca AJ, Gurgel RQ, Coelho IC-B, Fontes CJF, Marques ETA, Romero GAS, Teixeira MM, Siqueira AM, Barral AMP, Boaventura VS, Ramos F, Elias Júnior E, Moraes JC, Covas DT, Kalil J, Precioso AR, Whitehead SS, Esteves-Jaramillo A, Shekar T, Lee JJ, Macey J, Kelner SG, Coller BAG, Boulos FC, Nogueira ML. Live, attenuated, tetravalent butantan–dengue vaccine in children and adults. New Engl J Med. 2024;390(5):397-408. https://doi.org/10.1056/NEJMoa2301790
190. Tricou V, Yu D, Reynales H, Biswal S, Saez-Llorens X, Sirivichayakul C, Lopez P, Borja-Tabora C, Bravo L, Kosalaraksa P, Vargas LM, Alera MT, Rivera L, Watanaveeradej V, Dietze R, Fernando L, Wickramasinghe VP, Moreira ED Jr, Fernando AD, Gunasekera D, Luz K, Oliveira AL, Tuboi S, Escudero I, Hutagalung Y, Lloyd E, Rauscher M, Zent O, Folschweiller N, LeFevre I, Espinoza F, Wallace D. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, doubleblind, placebo-controlled trial.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Marcia Garnica, Fabianne Carlesse, Jessica Fernandes Ramos, Ana Verena Almeida Mendes, Larissa Gandolpho, Giovanni Luis Breda, Marcio Nucci, Clarisse Martins Machado
This work is licensed under a Creative Commons Attribution 4.0 International License.
